The signatures of five genes, TIMP1, PLEKHS1, RGN, LAMP3, and GADD45B, detected from the tumorigenesis process demonstrated robust prognostic significance for survival and relapse in GC patients, and this might result in the generation of potential molecular targets for the development of precision therapy [40]. This evidence concerns the gene RGN and gastric cancer.